The review found no eligible studies for this question.
Summary of findings table (sensitivity analysis): interventions… showed no clear difference in studies with gastric cancer participants in addition to eligible… compared with gastric carcinoma; GRADE not reported.
It is very uncertain whether summary of findings table (sensitivity analysis): interventions… changes sensitivity analysis, meta‐regression analysis, first part compared with gastric carcinoma (very low certainty).
Summary of findings table (sensitivity analysis): interventions… led to lower sensitivity analysis, only esophageal and GE‐junction cancer… compared with gastric carcinoma; GRADE not reported.
Summary of findings table (sensitivity analysis): interventions… showed no clear difference in sensitivity analysis, only gastric cancer participants compared with gastric carcinoma; GRADE not reported.
Summary of findings table (sensitivity analysis): interventions… probably leads to lower sensitivity analysis, meta‐regression analysis, second part compared with gastric carcinoma (moderate certainty).
Oral 5‐aminosalicylic acid showed no clear difference in failure to maintain clinical or endoscopic remission compared with comparator 5‐aminosalicylic acid formulation (low certainty).
The review found no eligible studies for this question.
Oral 5‐aminosalicylic acid showed no clear difference in adverse event compared with comparator 5‐aminosalicylic acid formulation (low certainty).
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with comparator 5‐aminosalicylic acid formulation (low certainty).
It is very uncertain whether oral 5‐aminosalicylic acid changes withdrawal due to adverse events compared with comparator 5‐aminosalicylic acid formulation (very low certainty).
Oral 5‐aminosalicylic acid showed no clear difference in exclusion/withdrawal after entry compared with comparator 5‐aminosalicylic acid formulation (moderate certainty).
Irinotecan probably leads to lower overall survival compared with non‐irinotecan‐containing regimens (moderate certainty).
Irinotecan showed no clear difference in overall survival ‐ Substitutive comparisons compared with non‐irinotecan‐containing regimens (moderate certainty).
Irinotecan showed no clear difference in overall survival ‐ Additive comparisons compared with non‐irinotecan‐containing regimens (low certainty).
It is very uncertain whether irinotecan changes overall survival ‐ Other comparisons compared with non‐irinotecan‐containing regimens (very low certainty).
Irinotecan may leads to higher tumour response compared with non‐irinotecan‐containing regimens (low certainty).
Irinotecan leads to lower progression‐free survival compared with non‐irinotecan‐containing regimens (high certainty).
Irinotecan showed no clear difference in progression‐free survival ‐ Substitutive comparison compared with non‐irinotecan‐containing regimens (moderate certainty).
Irinotecan showed no clear difference in treatment‐related death compared with non‐irinotecan‐containing regimens (low certainty).
The findings closest to your search, judged one by one by TypeSafe's Jev model.